Cellectis

Oct 04, 2018

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women's health based in Massachusetts, United States, is taking possession of Focal Therapeutics, a medical device company, for USD 125 million to complement its breast-conserving surgery permit...

Apr 12, 2018

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...

Sep 07, 2017

Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient’s death FDA has put two CAR-T trials on hold following a patient’s death, less than a week after the first ever CAR-T was approved by the US regulatory agency.  The patient (78) was suffering from r...

Jun 30, 2015

“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...